2026-02-24
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News CommentaryNEW YORK, Feb. 24, 2026 /CNW/ -- Mental health disorders--including depression, anxiety, PTSD, and bipolar disorder--continue to represent one of the largest and fastest-growing areas of unmet medical need worldwide. According to the World Health Organization, more than 970 million people globally are living with a mental health condition, driving significant demand for new, more effective treatment options. The global mental health therapeutics market is projected to surpass $40 billion over the next several years, supported by increased diagnosis rates, broader insurance coverage, and reduced stigma around seeking care. Active Companies in the biotech space of interest include: Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), Takeda Pharmaceutical Company Limited (NYSE:TAK) and Compass Pathways plc (NASDAQ:CMPS), Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb (NYSE:BMY).From a market perspective, the opportunity is large and growing. The global market for depression and anxiety treatments alone is estimated to exceed $50–60 billion annually, and the broader neuropsychiatric drug market is projected to surpass $150 billion by the end of the decade. As awareness and acceptance of new serotonin-based therapies increase, NSAs are positioned to capture a meaningful slice of this spend--especially if clinical data continues to show rapid symptom relief and improved patient outcomes. Investors tend to focus on upcoming clinical milestones, FDA pathways, and early commercialization signals as key value drivers.Longer term, NSAs also fit well into the acquisition and partnership strategies of large pharmaceutical companies looking to refresh aging CNS pipelines. A single successful NSA platform can support multiple indications, creating built-in expansion opportunities and upside optionality. As mental health remains a top global healthcare priority and capital continues flowing into differentiated CNS assets, NSAs are increasingly viewed as a scalable, high-impact category with the potential to generate strong returns for early and long-term investors alike.Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio - Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP) ("Helus"), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Directors. Dr. Lewis-Hall will also serve as Chair of the Company's Scientific Advisory Committee.Dr. Lewis-Hall is a pioneering physician and biopharmaceutical executive with more than 40 years of experience spanning clinical care, research, academia, corporate leadership, and public health advocacy. She began her medical career as a practicing psychiatrist, focusing on the impact of mental illness on families and communities.She later held senior leadership roles across the biopharmaceutical industry, including serving for more than a decade on Pfizer's Executive Leadership Team as Executive Vice President and Chief Medical Officer. In that role, she led a global medical organization operating in more than 125 countries and supporting a broad portfolio of medicines and vaccines. She subsequently served as Chief Patient Officer, advancing patient engagement, inclusion, and health equity initiatives across the enterprise. During her tenure, she also helped lead the spinout of SpringWorks Therapeutics and served on its Board of Directors, guiding the company through regulatory approvals and its evolution into a commercial-stage organization prior to its acquisition by Merck KGaA for approximately $3.4 billion. Dr. Lewis-Hall has also held senior leadership positions at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corporation, and Eli Lilly and Company.Dr. Lewis-Hall is a Distinguished Fellow of the American Psychiatric ...Full story available on Benzinga.com
